IceCure Medical Ltd (NASDAQ:ICCM - Get Free Report) traded down 0.4% on Thursday . The stock traded as low as $1.12 and last traded at $1.15. 341,936 shares changed hands during trading, a decline of 40% from the average session volume of 574,286 shares. The stock had previously closed at $1.16.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Alliance Global Partners raised IceCure Medical to a "strong-buy" rating in a research note on Friday, November 1st. HC Wainwright reaffirmed a "buy" rating and set a $2.50 price target on shares of IceCure Medical in a research report on Wednesday, November 27th.
Get Our Latest Stock Analysis on IceCure Medical
IceCure Medical Stock Down 2.6 %
The business has a fifty day simple moving average of $0.74 and a two-hundred day simple moving average of $0.71. The company has a market cap of $51.09 million, a PE ratio of -3.86 and a beta of 0.50. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC bought a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 66,400 shares of the company's stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 0.62% of the company's stock.
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Articles
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
